Akthelia Pharmaceuticals Announces Close of Follow-Up Pre-Seed Equity Round
Total of $200,000 in new equity
REYKJAVIK, Iceland -- Jan, 1, 2022 -- Akthelia Pharmaceuticals announced today that it has closed an follow-up to its earlier angel-led pre-seed funding round.
With further participation from existing investors, Akthelia Pharma has secured another US$200,000 to conduct further animal studies, define target product profile and position the company to be ready for institutional investment to take its lead program into the clinic.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.
Akthelia’s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.
Egill Masson CEO email@example.com
Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland